SCHEMBL19620598

SCHEMBL19620598

COc1ccc(C2OC(N)=C(OSCc3ccccc3)C2=O)cc1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 4/20 0.44
GAA P10253 1/20 0.44
RAB9A P51151 1/20 0.44
CDK1 P06493 1/20 0.42
CCNB1 P14635 1/20 0.42
GSK3A P49840 1/20 0.42
GSK3B P49841 1/20 0.42
CDK5 Q00535 1/20 0.42
CDK5R1 Q15078 1/20 0.42
PDE4A P27815 3/20 0.40
PDE4B Q07343 3/20 0.40
PDE4C Q08493 3/20 0.40
PDE4D Q08499 3/20 0.40
ACHE P22303 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19620501 0.85 MAPT (0.41) NPSR1RAB9AALDH1A1KDM4ECYP3A4
SCHEMBL19620502 0.85 LMNA (0.38) RAB9AALDH1A1KDM4ECYP3A4CYP2C9
SCHEMBL19620577 0.84 EGFR (0.37) RAB9AALDH1A1KDM4ECYP3A4CYP2C19
SCHEMBL19620603 0.84 POLB (0.50) RAB9AALDH1A1KDM4ECYP3A4CYP2C19
SCHEMBL19620665 0.83 HCRTR1 (0.38) NPSR1RAB9AALDH1A1MAPTSMN1; SMN2
SCHEMBL19620562 0.83 HSD11B1 (0.39) NPSR1RAB9AACHEALDH1A1KDM4E
SCHEMBL19620589 0.83 ADK (0.39) NPSR1GSK3BKDM4ECYP3A4CYP2C19
SCHEMBL19620497 0.83 PRNP (0.38) ALDH1A1CYP3A4CYP2C19MEN1KMT2A
SCHEMBL19620675 0.83 MAPT (0.42) NPSR1GAARAB9AACHEALDH1A1
SCHEMBL19620593 0.82 KDM4E (0.36) RAB9AALDH1A1KDM4ECYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2897607-B1 INHIBITORS OF BETA-HYDROLASE FOR TREATMENT OF CANCER RHODE ISLAND HOSPITAL (US) 2017-11-22 EP disclosed